稳定表达烟酸受体GPR109A的中国仓鼠卵巢细胞株的建立

目的 将GPR109A基因插入pEGFP-N3载体中构建重组质粒pEGFP-GPR109A,并建立稳定表达烟酸受体GPR109A的中国仓鼠卵巢(Chinese hamster ovary,CHO)细胞株.方法 构建重组质粒pEGFP-GPR109A,重组质粒转化大肠杆茵DH5a,重组质粒经PCR、酶切、测序验证正确后,应用脂质体转染技术将该质粒导入CHO细胞,用抗生素G418筛选稳定表达的细胞.倒置荧光显微镜观察克隆细胞株荧光信号,RT-PCR检测GPR109A基因mRNA表达,Westem Blotting检测绿色荧光蛋白与烟酸受体GPR109A的融合蛋白(GFP-GPR109A)的表达,激光共聚焦显微镜观察融合蛋白的细胞定位.结果 pEGFP-GPR109A真核表达质粒构建正确,融合蛋白GFP-GPR109A在CHO细胞中稳定表达,表达的融合蛋白主要定位于细胞膜.结论 成功构建pEGFP-GPR109A真核表达载体并建立其稳定表达的CHO细胞株;该细胞株的建立有助于GPR109A的更多生理病理功能研究,也为下一步抗动脉粥样硬化的药物筛选奠定了基础.     

Tumstatin-EGFP真核表达载体构建及稳定转染CHO细胞系的建立

目的 构建重组tumstatin-增强型绿色荧光蛋白(EGFP)的分泌型真核表达载体质粒,建立稳定转染的中国仓鼠卵巢细胞系(CHO-K1).方法 利用重叠多聚酶链反应(PCR)技术从pGEM-T/STL质粒和pEGFP-C2质粒中扩增出STL-EGFP,用DNA重组技术将片段定向插入pIRESneo3质粒中,经酶切和序列验证正确后,用lipofectamine 2000转染CHO-K1细胞,通过G418筛选建立稳定转染的CHO细胞系,用逆转录-PCR、Western blot检测tumstatin-EGFP的表达,用倒置荧光显微镜观察绿色荧光蛋白的表达.结果 重组真核表达载体正确构建并在CHO细胞获得稳定表达,tumstatin-EGFP基因整合入细胞基因组DNA,培养液上清有融合蛋白tumstatin-EGFP的分泌,绿色荧光蛋白的表达高达95%以上.结论 成功构建了质粒PIRESneo3-STL-EGFP,获得稳定表达tumstatin-EGFP的细胞系.     

pEGFP-C1-HSP27真核表达载体的构建及其稳定转染人胰腺癌SW1990细胞株的筛选

目的 构建表达热休克蛋白27( HSP27)的携带增强型绿色荧光蛋白(EGFP)的真核载体,建立稳定表达HSP72的人胰腺癌SW1990细胞株.方法 采用RT-PCR法从SW1990细胞中扩增出带有BamH Ⅰ、HindⅢ酶切位点的HSP27基因片段,插入真核表达载体pEGFP-C1,鉴定正确后用重组质粒转染SW1990细胞,并筛选稳转细胞株.荧光显微镜观察HSP72的定位,RT-PCR、蛋白质印迹法检测转染细胞HSP27的表达.结果 双酶切法鉴定和测序证实重组载体pEGFP-C1 -HSP27的DNA序列完全正确,并成功转染SW1990细胞,筛选获得稳转细胞株.荧光显微镜见EGFP主要分布在胞质中,转染细胞的HSP27mRNA表达明显增加(1.458±0.160比0.897 ±0.051,P＜0.05),且表达HSP27与EGFP的融合蛋白.结论 成功构建真核表达载体pEGFP-C1-HSP27,并筛选获得稳转的细胞株.     

携带融合基因穿梭质粒的构建及在人肝癌细胞中的表达

构建携带胸苷激酶(tk)与增强型绿色荧光蛋白(EGFP)融合基因穿梭质粒,并观察其在肝癌细胞系HepG2细胞中的表达。应用基因重组技术,构建EGFP与tk的融合表达穿梭质粒载体,经限制酶切鉴定和测序分析,脂质体转染将其导入HepG2中,48h后用荧光显微镜观察荧光的表达,RT-PCR法检测融合蛋白tk和EGFP的mRNA表达,四甲基偶氮唑蓝(MTT)实验检测转染融合蛋白载体后不同浓度的更昔洛韦(GCV)对HepG2细胞的细胞毒作用。酶切鉴定和测序分析证实重组质粒中插入融合目的基因片断及载体DNA大小、方向和插入位点正确,在转染此穿梭质粒的HepG2细胞中检测到绿色荧光蛋白的表达,RT-PCR检测到融合蛋白tk和EGFP的mRNA表达;GCV对转染了携带tk与EGFP融合基因穿梭质粒载体有明显的细胞毒作用。成功构建携带tk与EGFP融合基因穿梭质粒载体,转染人肝癌细胞株HepG2中tk和EGFP的独立表达没有受到影响,该载体可利用绿色荧光蛋白作为报告基因监测tk的表达并可用于肝癌的自杀基因治疗。     

PRL-3真核绿色荧光蛋白表达载体的构建及其在结肠癌SW480细胞中的表达

目的:构建蛋白酪氨酸磷酸酶-3(PRL-3)绿色荧光蛋白真核表达载体pEGFP-N1-PRL-3,为PRL-3基因功能研究奠定基础.方法:设计人PRL-3特异性引物,提取人大肠癌细胞系SW620细胞总RNA,应用RT-PCR方法获取人PRL-3全长cDNA,分别克隆至T载体及真核绿色荧光蛋白表达载体pEGFP-N1,应用PCR、酶切及DNA测序进行鉴定,确认后转染大肠癌细胞SW480,应用G418进行筛选获取PRL-3稳定表达细胞克隆,应用荧光定量PCR检测PRL-3基因表达.结果:获得522 bp的PRL-3基因编码序列并成功构建了真核绿色荧光蛋白表达载体pEGFPN1-PRL-3,该重组载体能够在SW480细胞中稳定表达.结论:成功构建真核绿色荧光蛋白表达载体pEGFP-N1-PRL-3和建立PRL-3稳定表达SW480细胞,为进一步深入研究PRL-3基因在大肠癌发生发展中的作用奠定基础.     

pEGFP—P21真核表达载体构建及在AGS细胞的表达定位

目的：构建人细胞周期蛋白依赖性激酶抑制蛋白（cyclin2dependent kinase inhibitor）P21^WAF基因的真核表达载体pEGFP—P21，建立稳定表达P21蛋白与pEGFP 融合蛋白的AGS细胞系，，为进一步研究P21对下游基因的调节作用提供实验基础。方法：用PCR法在pCDNA3-P21质粒中定向插入EcoR1、BarnH1酶切位点，扩增P21 cDNA；采用亚克隆技术构建绿色荧光蛋白pEGFP—C2-P21融合基因表达载体；PCR法、双酶切及测序鉴定。脂质体转染试剂将重组载体转染人胃癌AGS细胞系，G418筛选20天挑取表达pEGFP-P21的抗性克隆扩大培养、传代。荧光显微镜直接观察pEGFP—p21在细胞中的分布和定位，流式细胞术分析细胞周期。结果：鉴定结果表明重构载体pEGFP-P21序列和方向正确，借助绿色荧光蛋白直观观察P21定位于AGS细胞核。细胞周期分析细胞阻滞与G1／S期。结论：成功建立稳定表达pEGFP—P21的AGS细胞株，P21在细胞核内发挥周期阻滞的作用，P21对细胞周期的影响可能为其调节其他因子是始动因素，为进一步研究P21基因的功能奠定了实验基础。     

真核绿色荧光蛋白表达载体pEGFP-C1/PAK-1的构建及其在结直肠癌SW480细胞内的表达

目的:构建重组p21-activated kinase-1(PAK1)基因绿色荧光蛋白表达载体pEGFP-C1/PAK1,并转染入结直肠癌细胞SW480中表达.方法:在南方医科大学附属南方医院消化研究所实验室,从人类结直肠癌细胞株SW620细胞提取总RNA,经逆转录聚合酶链式反应获得人PAK1 cDNA片段,经过限制性内切酶进行酶切,T4连接酶进行连接,将目的基因克隆至真核绿色荧光蛋白表达载体pEGFP-C1上,然后转染结直肠癌细胞株SW480,观察其在细胞中表达.结果:重组载体经限制性内切酶酶切鉴定和DNA序列分析验证,显示插入载体的序列与目的基因一致,而且该重组载体能够在SW480细胞中表达.结论:成功构建了真核绿色荧光蛋白表达载体pEGFP-C1/PAK1,为研究PAK1在结直肠癌中的生物学功能奠定了基础.     

蛋白磷酸酶2A调节亚基PR55-γ基因克隆及真核细胞表达

目的:构建蛋白磷酸酶2A(PP2A)调节亚基PR55-γ(PPP2R2C)慢病毒过表达质粒,并在U87细胞株中稳定过表达PPP2R2C,探讨PPP2R2C对PP2A活性的影响。方法:通过反转录(RT)-PCR扩增PPP2R2C的编码序列并克隆至慢病毒载体PWPIR-增强型绿色荧光蛋白(EGFP)中,获得PWPIR-EGFP-PPP2R2C载体,通过酶切鉴定、质粒测序确定质粒克隆成功,用磷酸钙沉淀法将质粒转导至U87细胞中,流式细胞分析术检测U87细胞转导效率,蛋白质印迹法检测目的蛋白表达,通过PP2A蛋白免疫共沉淀法检测PP2A活性。结果:PWPIR-EGFP-PPP2R2C载体构建及U87细胞株稳转过表达PPP2R2C成功,并且细胞转导效率超过90%,外源性PPP2R2C表达率上升近23倍,过表达PPP2R2C能够增强PP2A活性。结论:PWPIR-EGFP-PPP2R2C载体构建成功,并通过慢病毒转导细胞U87细胞株表达PPP2R2C成功,过表达PPP2R2C能够增强PP2A活性,为进一步研究PPP2R2C功能奠定基础。     

蛋白激酶SGK3基因的克隆及其在乳腺癌细胞中的表达

目的探讨通过克隆蛋白激酶(SGK)3基因并将其转染乳腺癌MCF-7细胞建立高表达SGK3的MCF-7细胞系的稳态性。方法利用真核表达载体N-端增强型绿色荧光蛋白(p EGFP-N1)通过基因克隆技术构建重组质粒,通过菌落PCR和DNA测序方法对重组质粒进行鉴定。通过PEI介导将重组质粒p EGFP-N1-SGK3转染至乳腺癌MCF-7细胞中,荧光显微镜和Western印迹方法对基因转染效率以及融合蛋白GFP-SGK3的表达进行鉴定。结果成功构建了真核表达质粒,将其命名为p EGFP-N1-SGK3;在荧光显微镜下可见多数细胞发出绿色荧光,表明获得了较高的转染效率;Western印迹结果显示,在转染p EGFP-N1-SGK3的细胞中可见阳性条带,而MCF-7亲本细胞和转染空载体的对照组细胞无阳性条带。结论成功构建了重组质粒p EGFP-N1-SGK3,获得了稳定表达融合蛋白GFP-SGK3的MCF-7细胞系,可用于后续SGK3细胞内功能的研究。     

结核分枝杆菌Hsp65与IL-2融合蛋白稳定表达细胞系的建立

目的构建了表达结核分枝杆菌Hsp65与IL-2融合蛋白的真核表达载体;获得重组质粒稳定转染的P815细胞系。方法将Hsp65与IL-2基因分别克隆至真核表达载体pcDNA3.1,转化DH5α菌株感受态细胞,获得阳性重组质粒Hsp65-IL-2-pcDNA3.1。在阳离子聚合物作用下,重组质粒转染与BALB/c遗传背景一致的P815(H-2d)细胞。G418筛选抗性克隆,免疫荧光检测融合蛋白的表达。结果真核质粒转染的阳性克隆细胞,经RT-PCR检测到Hsp65与IL-2融合蛋白mRNA水平的表达,分别用抗Hsp65和IL-2的单抗进行间接免疫荧光检测,可在转染重组质粒的P815细胞膜上观察到较强的绿色荧光。结论获得表达Hsp65与IL-2融合蛋白的稳定细胞系,为其CTL研究提供了合适的靶细胞。     

不含氨基端的人磷脂酶D2在大肠杆菌中的表达及其抗炎活性研究(英文)

目的研究重组人磷脂酶D2(rhPLD2)在体内外的免疫学活性,尤其是研究其抗炎活性。方法将编码rh-PLD2的cDNA片段经RT-PCR克隆至pET-30a载体中,并纯化来自包涵体中由大肠杆菌表达的rhPLD2重组蛋白。通过测定豚鼠慢性哮喘模型的支气管肺泡灌洗液(BALF)和血液中嗜酸性粒细胞的数量及肺组织中IL-5、MMP-9的表达来评定rhPLD2重组蛋白的抗炎活性。结果从人Daudi细胞中获得了不含膜结合部位及信号肽的,可编码631个氨基酸的rh-PLD2 cDNA序列(GenBank登录号:AY178289)。rhPLD2重组蛋白的纯度约76%,其生物活性达到50.9745U/L(0.9212g/L)。用rhPLD2治疗慢性哮喘动物模型证实了其的抗炎功效。包括:能下调炎性细胞因子IL-5的表达。结论由大肠杆菌表达的rhPLD2重组蛋白具有抗炎活性。     

可溶性肿瘤坏死因子相关凋亡诱导配体重组腺病毒载体的构建及其在肝癌细胞株中的表达

肿瘤坏死因子相关凋亡诱导配体（TRAIL）能诱导30余种人类肿瘤细胞凋亡，在抗肿瘤治疗中具有广阔应用前景。目的：构建携带可溶性TRAIL基因的复制缺陷型重组腺病毒载体，鉴定其在肝癌细胞株中的表达。方法：以重叠延伸聚合酶链反应（PCR）扩增白细胞介素（IL）-2信号肽和TRAIL膜外区融合片段，克隆于腺病毒穿梭质粒pAdTrack—CMV，转化含复制缺陷型腺病毒骨架质粒pAdEasy-1的大肠杆菌pAdBJ5183，经细菌内同源重组产生重组腺病毒Ad-IL-2-TRAIL，以脂质体法转染HEK293细胞包装病毒，感染肝癌细胞株HepG2．荧光显微镜下观察增强型绿色荧光蛋白（EGFP）的表达。结果：成功构建了携带可溶性TRAIL基因的复制缺陷型重组腺病毒载体。病毒感染HepG2细胞48h后，超过95％的细胞中出现绿色荧光。结论：所构建的复制缺陷型重组腺病毒Ad—IL-2-TRAIL可在肝癌细胞中高效表达可溶性TRAIL，为进一步行肿瘤TRAIL基因冶疗提供了实验依据。     

幽门螺杆菌尿素通道蛋白基因UreI的真核载体构建、表达及抗原性研究

目的构建含人幽门螺杆菌(Helicobacter pylori,H.pylori)尿素通道蛋白编码基因(UreI)的真核表达的重组载体,并在COS-7细胞中表达,为核酸疫苗的开发奠定基础。方法以原核表达质粒pET32a(+)/UreI为模板,扩增UreI编码基因片段,将目的基因与同样进行酶切、纯化的载体pEGFP-N1进行连接,而后转化并筛选含有目的基因的重组载体pEG-FP-N1/UreI,并在COS-7细胞中表达,以荧光蛋白和Western blot法检测其表达产物。结果经酶切、测序证实插入的基因片段为H.pyloriUreI蛋白编码基因;荧光显微镜下和Western blot法等检测显示,该重组质粒能够在COS-7细胞中表达目的蛋白,同时能够被H.pylori阳性患者血清所识别。结论成功地构建了真核重组载体pEGFP-N1/UreI,并在COS-7细胞中表达。     

Construction of the Eukaryotic Expression Vector with EGFP and hVE GF121 Gene and its Expression in Rat Mesenchymal Stem Cells

Objectives To construct a recombinant plasmid carrying enhanced green fluorescent protein (EGFP) and human vascular endothelial growth factor (VEGF) 121 gene and detect its expression in rat mesenchymal stem cells (MSCs). Methods Human VEGF121 cDNA was amplified with polymerase chain reaction (PCR) from pCD/hVEGF121 and was inserted into the eukaryotic expression vector pEGFPC1. After being identified with PCR, double enzyme digestion and DNA sequencing. The recombinant plasmid pEGFP/hVEGF121 was transferred into rat MSCs with lipofectamine. The expression of EGFP/VEGF121 fusion protein were detected with fluorescence microscope and immunocytochemical staining respectively. Results The recombinant plasmid was confirmed with PCR, double enzyme digestion and DNA sequencing. The fluorescence microscope and immunocytochemical staining results showed that the EGFP and VEGF121 protein were expressed in MSCs 48h after transfection.Conclusions The recombinant plasmid carrying EGFP and human VEGF was successfully constructed and expressed positively in rat MSCs. It offers a promise tool for further research on differentiation of MSCs and VEGF gene therapy for ischemial cardiovascular disease.     

稳定高表达增强型绿色荧光蛋白基因膀胱癌细胞株的构建

目的 建立稳定高表达增强型绿色荧光蛋白(EGFP)基因的膀胱癌细胞株(KU-7/EGFP)并观察其生物特性的变化.方法 利用脂质体将EGFP真核表达质粒(pEGFP-N3)转染至人膀胱癌细胞株KU-7,经过G418筛选和克隆化培养,荧光显微镜及流式细胞仪观察转染EGFP基因的KU-7在裸鼠体内外的表达情况,分析转染细胞生物学行为变化.结果 KU-7/EGFP在荧光显微镜下发出绿色荧光,能稳定、高效和持久地表达EGFP,与未转染细胞比较,其生物学特性未改变.KU-7/EGFP接种于裸鼠皮下5 d后成瘤,14 d后肿瘤直径达到15 mm.结论 成功建立了稳定高表达EGFP的膀胱癌细胞株KU-7-EGFP,其生物学特性未变.     

锚定修饰的真核表达质粒pcDNA3.1（＋）-rmCGβ-IgGFc-GPI的构建及鉴定

目的为研究锚定修饰的rmCGβ-IgGFc-GPI的新功能和免疫治疗奠定基础。方法应用基因工程技术将pCI-IgGFc-GPI质粒经双酶切后,插入pcDNA3.1（＋）真核表达质粒,构建重组真核表达质粒pcDNA3.1（＋）-Ig-GFc-GPI,然后再插入经双酶切的恒河猴绒毛膜促性腺激素β亚基（rmCGβ亚基）,构建重组真核表达质粒pcD-NA3.1（＋）-rmCGβ-IgGFc-GPI,经限制内切酶酶切分析及测序鉴定正确后,用脂质体转染技术转染B16细胞,流式细胞仪技术和细胞免疫荧光法检测B16细胞中表达的IgGFc段融合蛋白。结果酶切和测序证明正确构建了真核表达质粒pcDNA3.1（＋）-rmCGβ-IgGFc-GPI,流式细胞仪技术和细胞免疫荧光法证实该质粒能在B16真核细胞中正确表达目的蛋白;建立了稳定的细胞株B16/pcDNA3.1（＋）-rmCGβ-IgGFc-GPI。结论锚定修饰的rmCGβ亚基的真核表达质粒pcDNA3.1（＋）-rmCGβ-IgGFc-GPI成功构建,且能在B16细胞内表达;为进一步研究锚定修饰的rmCGβ-IgGFc-GPI的新功能和免疫治疗奠定了基础。     

Construction of a targeting adenoviral vector carrying AFP promoter for expressing EGFP gene in AFP-producing hepatocarcinoma cell

AIM:To construct a recombinant adenoviral vector carrying AFP promoter and EGFP gene for specific expression of EGFP gene in AFP producing hepatocellular carcinoma (HCC) HepG2 cells.METHODS: Based on the Adeno-X^TM expression system, the human immediate early cytomegalovirus promoter (PCMV IE)was removed from the plasmid, pshuttle,and replaced by a 0.3 kb (α-fetoprotein (AFP) promoter that was synthesized by polymerase chain reaction (PCR).The enhanced green fluorescent protein (EGFP) gene was inserted into the multiclone site (MCS),and then the recombinant adenovirus vector carrying the 0.3kb AFP promoter and EGFP gene was constructed.Cells of a normal liver cell line (LO2),a hepatocarcinoma cell line (HepG2) and a cervical cancer cell line (HeLa) were transfected with the adenovirus.Northern blot and fluorescence microscopy were used to detect the expression of the EGFP gene at mRNA or protein level in three different cell lines.RESULTS:The 0.3kb AFP promoter was synthesized through PCR from the human genome.The AFP promoter and EGFP gene were directly inserted into the plasmid pshuttle as confirmed by restriction digestion and DNA sequencing.Northern blot showed that EGFP gene was markedly transcribed in HepG2 cells,but only slightly in LO2 and HeLa cells.In addition,strong green fluorescence was observed in HepG2 cells under a fluorescence microscopy,but fluorescence was very weak in LO2 and HeLa cells.CONCLUSION:Under control of the 0.3kb human AFP promoter, the recombinant adenovirus vector carrying EGFP gene can be specially expressed in AFP-producing HepG2 cells,Therefore,this adenovirus system can be used as a novel,potent and specific tool for gene-targeting therapy for the AFP positive primary hepatocellular carcinoma,     

Construction of a targeting adenoviral vector carrying AFP promoter for expressing EGFP gene in AFP-producing hepatocarcinoma cell

AIM:To construct a recombinant adenoviral vector carryingAFPpromoter and EGFPgene for specific expression of EGFPgene in AFP producing hepatocellular carcinoma (HCC)HepG2 cells.METHODS:Based on the Adeno-X~(TM) expression system,thehuman immediate early cytomegalovirus promoter (P_(CMVIE))was removed from the plasmid,pshuttle,and replaced by a0.3 kb α-fetoprotein (AFP) promoter that was synthesizedby polymerase chain reaction (PCR).The enhanced greenfluorescent protein (EGFP) gene was inserted into the multi-clone site (MCS),and then the recombinant adenovirusvector carrying the 0.3 kb AFP promoter and EGFP genewas constructed.Cells of a normal liver cell line (LO2),ahepatocarcinoma cell line (HepG2) and a cervical cancercell line (HeLa) were transfectecl with the adenovirus.Northern blot and fluorescence microscopy were used todetect the expression of the EGFPgene at mRNA or proteinlevel in three different cell lines.RESULTS:The 0.3 kb AFP promoter was synthesizedthrough PCR from the human genome.The AFP promoterand EGFP gene were directly inserted into the plasmidpshuttle as confirmed by restriction digestion and DNAsequencing.Northern blot showed that EGFP gene wasmarkedly transcribed in HepG2 cells,but only slightly in LO2and HeLa cells.In addition,strong green fluorescence wasobserved in HepG2 cells under a fluorescence microscopy,but fluorescence was very weak in LO2 and HeLa cells.CONCLUSION:Under control of the 0.3 kb human AFPpromoter,the recombinant adenovirus vector carrying EGFPgene can be specially expressed in AFP-producing HepG2cells.Therefore,this adenovirus system can be used as anovel,potent and specific tool for gene-targeting therapyfor the AFP positive primary hepatocellular carcinoma.     

Fusion of EGFP and porcine α 1,3GT genes decrease GFP expression

ObjectiveTo investigate the effect of fusion proteins expressed by the fused gene of porcine α 1, 3 galactosyltransferase (α1, 3 GT) and enhanced green fluorescent protein (EGFP) on the green fluorescence intensity of EGFP.MethodsThe fragment containing α 1, 3GT was firstly recovered after the pcDNA3.1- α 1, 3GT recombinant vector were digested with Bam HI and Eco RI, and then, the resultant fragment was ligated to the pEGFP-N1 vector which was also digested with the same enzymes. The new recombinant eukaryotic expression pEGFP/α 1, 3GT vector was obtained and sequenced. The pEGFP/α 1, 3GT was used to transfect human lung carcinoma cells A549 and HEKC 293FT, and the expression of EGFP was quantitatively analyzed by fluorescent microscope and flow cytometry.ResultsThe positive percentage of A549 was 80.5%, and that of 293 FT was 86.5% 48 hours after the two cell lines both were transfected by pEGFP-N1. The positive percentage of A549 was 75.8%, and that of 293 FT was 81.2% 48 hours after the two cell lines were transfected by pEGFP/α 1, 3GT. The mean fluorescence intensities of A549 transfected with pEGFP-N1 and pEGFP/α 1, 3GT were 1.21 and 0.956, respectively when compared with that of A549 without transfection. Meanwhile, the those of the 293FT that were transfected with pEGFP-N1 and pEGFP/α 1, 3GT were 7.66 and 1.00, respectively when compared with that of 293FT cells without transfection.ConclusionsThese results suggested that the expression of EGFP gene fused with porcine α 1, 3GT gene was partly inhibited.